NEW YORK – SomaLogic said on Thursday that it has launched a collaboration with Amgen to use its SomaScan proteomics platform within Amgen's drug discovery and development programs.
Under the agreement, SomaLogic will analyze more than 40,000 samples, including from Amgen clinical trials.
The deal builds on a 2018 agreement between SomaLogic and Amgen subsidiary Decode Genetics that called for Somalogic to analyze up to 40,000 of Decode's patient samples.
The SomaScan platform uses SomaLogic's Somamer affinity reagents to measure protein expression in patient samples. The current version of the platform covers around 5,000 proteins.
"Profiling proteins at scale has the potential to impact clinical or basic research studies of almost any disease or condition, and we offer unmatched scale and reliability," SomaLogic CEO Roy Smythe said in a statement.
"Our insights from earlier studies leveraging SomaLogic's proteomic data are beginning to reveal a deeper understanding of human health," said Kari Stefansson, founder and CEO of Decode Genetics. "This new agreement will further enhance these efforts as we seek to enable the discovery of new drug targets and identify the individuals who will respond to specific treatments being developed by Amgen."
Financial and other terms of the agreement were not disclosed.